VVT Medical

Varicose Vein Treatment

Health Tech & Life Sciences
Public on TSXV on Jul 2025

Company Overview

Snapshot

Founded in January 2007, VVT Medical operates with 11–50 employees. The company has raised a total of $2.6M across two funding rounds, attracting I3 Capital Group. A significant milestone was achieved in July 2025 when VVT Medical Inc. commenced trading on the TSX Venture Exchange.

Business overview

VVT Medical specializes in the research, development, manufacturing, and commercialization of minimally invasive, non-thermal, non-tumescent solutions for treating varicose veins. The company's core technology, the ScleroSafe platform, enables physicians to perform quick, office-based procedures without tumescent anesthesia or costly capital equipment. VVT Medical's solutions are designed for various outpatient settings, including vein clinics, day care clinics, angio suites, catheterization laboratories, and hospitals, addressing conditions such as severely dilated Great Saphenous Vein (GSV) and reflux.

Strategic signal

In June 2026, VVT Medical significantly expanded its European commercial footprint by signing an exclusive distribution agreement in Greece and also entered the Dominican Republic market by appointing Antilles Medical as its exclusive distributor. These strategic partnerships indicate a strong focus on international market penetration and commercial scaling for its ScleroSafe system, signaling potential for accelerated revenue growth and broader adoption of its varicose vein treatment solutions.

Company Intelligence Q&A

What was a key market expansion for VVT Medical in June 2026?
In June 2026, VVT Medical expanded its European commercial footprint through an exclusive distribution agreement in Greece and also entered the Dominican Republic market by appointing Antilles Medical as its exclusive distributor.
When did VVT Medical commence trading on the TSX Venture Exchange?
VVT Med Inc. announced the commencement of trading on the TSX Venture Exchange in July 2025.
What significant distribution deal did VVT Med sign in November 2025?
In November 2025, VVT Med signed a $3.7 million distribution agreement in India, alongside achieving a European sales milestone and announcing a proposed debt settlement.
What was a recent clinical validation for VVT Medical's ScleroSafe system?
In April 2026, VVT Med announced positive clinical data for its ScleroSafe system, which was published in the peer-reviewed Indian Journal of Vascular and Endovascular Surgery.
What was a recent financial restructuring move by VVT Med?
In August 2026, VVT Med announced a debt settlement and equity incentive grants to strengthen its capital structure.

External links